India Gene Therapy Market By Indication (Large B-Cell Lymphoma, Multiple Myeloma, Spinal Muscular Atrophy (SMA), Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Inherited Retinal Disease, Beta-Thalassemia Major/SCD, Others), By Vector Type (Lentivirus, RetroVirus & gamma RetroVirus, AAV, Modified Herpes Simplex Virus, Adenovirus, Others), By Route of Administration (Intravenous, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F
India Gene Therapy Market was valued at USD 472.24 Million in 2024 and is expected to reach USD 1,203.38 Million by 2030 with a CAGR of 16.83% during the forecast period. The India gene therapy market is experiencing significant growth, driven by advancements in biotechnology, increasing prevalence of genetic disorders, and government initiatives to support healthcare innovation. The rising incidence of inherited conditions such as Spinal Muscular Atrophy (SMA), Beta-Thalassemia, and various types of cancers has spurred the demand for gene therapies as potential treatments. Key technologies like CRISPR-Cas9 and other gene-editing tools are enabling precise, effective therapies, further fueling market growth. Additionally, the increasing investment in biotechnology research and collaborations between pharmaceutical companies and academic institutions are accelerating the development of new gene therapies.
However, the market also faces several challenges. One of the major barriers is the high cost of gene therapies, which limits patient access, particularly in lower-income segments of the population. Although the Indian government is promoting the development of biotech innovations, there are still regulatory hurdles that slow the approval process for new therapies. Furthermore, a lack of sufficient infrastructure and expertise in some regions can hinder the widespread adoption of gene therapies, particularly in rural and underserved areas. Despite these challenges, the market is expected to continue expanding as solutions to these issues evolve, making gene therapies more accessible and affordable in the long term.
Key Market Drivers
Growing Healthcare Infrastructure
India's growing healthcare infrastructure is one of the key drivers for the advancement of various healthcare markets, including gene therapy. As the nation continues to invest in and develop its healthcare system, it creates a conducive environment for innovations in treatment, including the adoption of advanced therapies like gene therapy. A robust healthcare infrastructure ensures better access to medical services across both rural and urban areas, facilitating the implementation of cutting-edge therapies and technologies. As of March 31, 2023, India boasts a total of 1,69,615 Sub-Centres (SCs), 31,882 Primary Health Centres (PHCs), 6,359 Community Health Centres (CHCs), 1,340 Sub-Divisional/District Hospitals (SDHs), 714 District Hospitals (DHs), and 362 Medical Colleges (MCs). These facilities collectively serve both rural and urban populations, ensuring widespread access to healthcare services.
The expansion of healthcare infrastructure is further complemented by a significant workforce of healthcare professionals. This growing pool of doctors, specialists, nurses, and paramedical staff is crucial for the successful implementation of new therapies, as it ensures the availability of skilled personnel to deliver treatments effectively. The healthcare workforce includes 2,39,911 Health Workers (Male + Female) at SCs, 40,583 Doctors/Medical Officers at PHCs, 26,280 Specialists & Medical Officers at CHCs, and 45,027 Doctors and Specialists at SDHs and DHs. Additionally, there are 47,932 Staff Nurses at PHCs, 51,059 Nursing Staff at CHCs, and 1,35,793 Paramedical Staff at SDHs and DHs across India.
Key Market Challenges
Regulatory and Approval Delays
Workforce shortages in healthcare represent a significant challenge for the India Gene Therapy Market, as the demand for health check-up services continues to rise. The shortage of qualified healthcare professionals, including physicians, nurses, technicians, and administrative staff, is a key barrier to the efficient delivery of preventive healthcare services and the expansion of health check-up offerings across the Kingdom.
One of the primary issues contributing to workforce shortages in Saudi Arabia's healthcare sector is the imbalance between the growing demand for healthcare services and the limited supply of skilled professionals. As the population ages and the prevalence of chronic diseases such as diabetes, heart disease, and hypertension rises, the need for regular health check-ups and preventive care has intensified. However, the healthcare workforce is often stretched thin, unable to meet the increasing demand for these services. This strain on resources leads to longer wait times, reduced quality of care, and, in some cases, compromised patient safety.
Moreover, the specialized skills required to administer comprehensive health check-ups—including diagnostic screenings, laboratory tests, imaging, and consultations with specialists—demand highly trained personnel. The lack of sufficient numbers of qualified professionals, particularly in rural and remote areas, further exacerbates the challenge. In many regions, patients may face difficulty accessing timely health check-ups due to the limited availability of trained staff, hindering the ability to meet the rising demand for preventive healthcare.
Key Market Trends
Advancements in Biotechnology and Gene Editing
Advancements in Biotechnology and Gene Editing are emerging as key trends driving the growth of the gene therapy market in India. As technological innovation accelerates globally, India is benefiting from cutting-edge biotechnology and gene-editing technologies that enable the development of more effective and targeted treatments for genetic disorders. Tools like CRISPR-Cas9 and Zinc Finger Nucleases (ZFNs) are at the forefront of gene editing, offering unprecedented precision in altering genes to correct genetic defects or treat various diseases.
In India, these advancements are particularly impactful in the context of genetic disorders such as Spinal Muscular Atrophy (SMA), Beta-Thalassemia, and Sickle Cell Disease (SCD), where gene therapy offers the potential for curative treatments rather than merely managing symptoms. The increased focus on biotechnology has led to the establishment of several biotech research hubs and institutions across the country, particularly in cities like Bengaluru, Hyderabad, and Mumbai, where research and development efforts are geared toward advancing gene therapy technologies.
Indian biotech companies are actively investing in the development of gene editing tools, bringing together expertise from global and local stakeholders to create therapies tailored to the Indian population. The growing collaboration between Indian pharmaceutical companies and international biotech firms is also contributing to advancements in gene therapy. This trend is supported by government initiatives, including funding for biotechnology research and efforts to strengthen intellectual property protections for innovations in the gene editing space.
Key Market Players
In this report, the India Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the India Gene Therapy Market.
Available Customizations:
India Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
However, the market also faces several challenges. One of the major barriers is the high cost of gene therapies, which limits patient access, particularly in lower-income segments of the population. Although the Indian government is promoting the development of biotech innovations, there are still regulatory hurdles that slow the approval process for new therapies. Furthermore, a lack of sufficient infrastructure and expertise in some regions can hinder the widespread adoption of gene therapies, particularly in rural and underserved areas. Despite these challenges, the market is expected to continue expanding as solutions to these issues evolve, making gene therapies more accessible and affordable in the long term.
Key Market Drivers
Growing Healthcare Infrastructure
India's growing healthcare infrastructure is one of the key drivers for the advancement of various healthcare markets, including gene therapy. As the nation continues to invest in and develop its healthcare system, it creates a conducive environment for innovations in treatment, including the adoption of advanced therapies like gene therapy. A robust healthcare infrastructure ensures better access to medical services across both rural and urban areas, facilitating the implementation of cutting-edge therapies and technologies. As of March 31, 2023, India boasts a total of 1,69,615 Sub-Centres (SCs), 31,882 Primary Health Centres (PHCs), 6,359 Community Health Centres (CHCs), 1,340 Sub-Divisional/District Hospitals (SDHs), 714 District Hospitals (DHs), and 362 Medical Colleges (MCs). These facilities collectively serve both rural and urban populations, ensuring widespread access to healthcare services.
The expansion of healthcare infrastructure is further complemented by a significant workforce of healthcare professionals. This growing pool of doctors, specialists, nurses, and paramedical staff is crucial for the successful implementation of new therapies, as it ensures the availability of skilled personnel to deliver treatments effectively. The healthcare workforce includes 2,39,911 Health Workers (Male + Female) at SCs, 40,583 Doctors/Medical Officers at PHCs, 26,280 Specialists & Medical Officers at CHCs, and 45,027 Doctors and Specialists at SDHs and DHs. Additionally, there are 47,932 Staff Nurses at PHCs, 51,059 Nursing Staff at CHCs, and 1,35,793 Paramedical Staff at SDHs and DHs across India.
Key Market Challenges
Regulatory and Approval Delays
Workforce shortages in healthcare represent a significant challenge for the India Gene Therapy Market, as the demand for health check-up services continues to rise. The shortage of qualified healthcare professionals, including physicians, nurses, technicians, and administrative staff, is a key barrier to the efficient delivery of preventive healthcare services and the expansion of health check-up offerings across the Kingdom.
One of the primary issues contributing to workforce shortages in Saudi Arabia's healthcare sector is the imbalance between the growing demand for healthcare services and the limited supply of skilled professionals. As the population ages and the prevalence of chronic diseases such as diabetes, heart disease, and hypertension rises, the need for regular health check-ups and preventive care has intensified. However, the healthcare workforce is often stretched thin, unable to meet the increasing demand for these services. This strain on resources leads to longer wait times, reduced quality of care, and, in some cases, compromised patient safety.
Moreover, the specialized skills required to administer comprehensive health check-ups—including diagnostic screenings, laboratory tests, imaging, and consultations with specialists—demand highly trained personnel. The lack of sufficient numbers of qualified professionals, particularly in rural and remote areas, further exacerbates the challenge. In many regions, patients may face difficulty accessing timely health check-ups due to the limited availability of trained staff, hindering the ability to meet the rising demand for preventive healthcare.
Key Market Trends
Advancements in Biotechnology and Gene Editing
Advancements in Biotechnology and Gene Editing are emerging as key trends driving the growth of the gene therapy market in India. As technological innovation accelerates globally, India is benefiting from cutting-edge biotechnology and gene-editing technologies that enable the development of more effective and targeted treatments for genetic disorders. Tools like CRISPR-Cas9 and Zinc Finger Nucleases (ZFNs) are at the forefront of gene editing, offering unprecedented precision in altering genes to correct genetic defects or treat various diseases.
In India, these advancements are particularly impactful in the context of genetic disorders such as Spinal Muscular Atrophy (SMA), Beta-Thalassemia, and Sickle Cell Disease (SCD), where gene therapy offers the potential for curative treatments rather than merely managing symptoms. The increased focus on biotechnology has led to the establishment of several biotech research hubs and institutions across the country, particularly in cities like Bengaluru, Hyderabad, and Mumbai, where research and development efforts are geared toward advancing gene therapy technologies.
Indian biotech companies are actively investing in the development of gene editing tools, bringing together expertise from global and local stakeholders to create therapies tailored to the Indian population. The growing collaboration between Indian pharmaceutical companies and international biotech firms is also contributing to advancements in gene therapy. This trend is supported by government initiatives, including funding for biotechnology research and efforts to strengthen intellectual property protections for innovations in the gene editing space.
Key Market Players
- Novartis India Ltd.
- Bharat Biotech
- Cipla Limited
- Zydus Group
- Biocon Limited
- Dr. Reddy's Laboratories
- Intas Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd.
- Serum Institute of India
- Panacea Biotec
In this report, the India Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- India Gene Therapy Market, By Indication:
- Large B-Cell Lymphoma
- Multiple Myeloma
- Spinal Muscular Atrophy (SMA)
- Acute Lymphoblastic Leukemia (ALL)
- Melanoma (lesions)
- Inherited Retinal Disease
- Beta-Thalassemia Major/SCD
- Others
- India Gene Therapy Market, By Vector Type:
- Lentivirus
- RetroVirus & gamma RetroVirus
- AAV
- Modified Herpes Simplex Virus
- Adenovirus
- Others
- India Gene Therapy Market, By Route of Administration:
- Intravenous
- Others
- India Gene Therapy Market, By Region:
- East India
- West India
- North India
- South India
Company Profiles: Detailed analysis of the major companies present in the India Gene Therapy Market.
Available Customizations:
India Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. INDIA GENE THERAPY MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Indication (Large B-Cell Lymphoma, Multiple Myeloma, Spinal Muscular Atrophy (SMA), Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Inherited Retinal Disease, Beta-Thalassemia Major/SCD, Others)
4.2.2. By Vector Type (Lentivirus, RetroVirus & gamma RetroVirus, AAV, Modified Herpes Simplex Virus, Adenovirus, Others)
4.2.3. By Route of Administration (Intravenous, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Indication
4.3.2. By Vector Type
4.3.3. By Route of Administration
4.3.4. By Region
5. EAST INDIA GENE THERAPY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication
5.2.2. By Vector Type
5.2.3. By Route of Administration
6. WEST INDIA GENE THERAPY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Vector Type
6.2.3. By Route of Administration
7. NORTH INDIA GENE THERAPY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Vector Type
7.2.3. By Route of Administration
8. SOUTH INDIA GENE THERAPY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Vector Type
8.2.3. By Route of Administration
9. MARKET DYNAMICS
9.1. Drivers
9.2. Challenges
10. MARKET TRENDS & DEVELOPMENTS
10.1. Recent Developments
10.2. Product Launches
10.3. Mergers & Acquisitions
11. POLICY & REGULATORY LANDSCAPE
12. INDIA ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Novartis India Ltd.
13.1.1. Business Overview
13.1.2. Company Snapshot
13.1.3. Products & Services
13.1.4. Financials (In case of listed)
13.1.5. Recent Developments
13.1.6. SWOT Analysis
13.2. Bharat Biotech
13.3. Cipla Limited
13.4. Zydus Group
13.5. Biocon Limited
13.6. Dr. Reddy's Laboratories
13.7. Intas Pharmaceuticals Ltd.
13.8. Sun Pharmaceutical Industries Ltd.
13.9. Serum Institute of India
13.10. Panacea Biotec
14. STRATEGIC RECOMMENDATIONS
15. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. INDIA GENE THERAPY MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Indication (Large B-Cell Lymphoma, Multiple Myeloma, Spinal Muscular Atrophy (SMA), Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Inherited Retinal Disease, Beta-Thalassemia Major/SCD, Others)
4.2.2. By Vector Type (Lentivirus, RetroVirus & gamma RetroVirus, AAV, Modified Herpes Simplex Virus, Adenovirus, Others)
4.2.3. By Route of Administration (Intravenous, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Indication
4.3.2. By Vector Type
4.3.3. By Route of Administration
4.3.4. By Region
5. EAST INDIA GENE THERAPY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication
5.2.2. By Vector Type
5.2.3. By Route of Administration
6. WEST INDIA GENE THERAPY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Vector Type
6.2.3. By Route of Administration
7. NORTH INDIA GENE THERAPY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Vector Type
7.2.3. By Route of Administration
8. SOUTH INDIA GENE THERAPY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Vector Type
8.2.3. By Route of Administration
9. MARKET DYNAMICS
9.1. Drivers
9.2. Challenges
10. MARKET TRENDS & DEVELOPMENTS
10.1. Recent Developments
10.2. Product Launches
10.3. Mergers & Acquisitions
11. POLICY & REGULATORY LANDSCAPE
12. INDIA ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Novartis India Ltd.
13.1.1. Business Overview
13.1.2. Company Snapshot
13.1.3. Products & Services
13.1.4. Financials (In case of listed)
13.1.5. Recent Developments
13.1.6. SWOT Analysis
13.2. Bharat Biotech
13.3. Cipla Limited
13.4. Zydus Group
13.5. Biocon Limited
13.6. Dr. Reddy's Laboratories
13.7. Intas Pharmaceuticals Ltd.
13.8. Sun Pharmaceutical Industries Ltd.
13.9. Serum Institute of India
13.10. Panacea Biotec
14. STRATEGIC RECOMMENDATIONS
15. ABOUT US & DISCLAIMER
